Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302

A Study of Patients With Fabry Disease (US Specific)

NCT06906367 ·Status: RECRUITING

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

NCT02194985 ·Status: COMPLETED ·Phase: PHASE3

Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201

NCT04999059 ·Status: TERMINATED

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00283933 ·Status: COMPLETED ·Phase: PHASE2

A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190

NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00196716 ·Status: COMPLETED ·Phase: PHASE2

Characterisation of Heart Involvement in Fabry Disease With T1 Mapping

NCT04708301 ·Status: COMPLETED

Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

NCT06308718 ·Status: TERMINATED

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760 ·Status: COMPLETED ·Phase: PHASE3

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Treatment Protocol of Replagal for Patients With Fabry Disease

NCT01031173 ·Status: NO_LONGER_AVAILABLE

A Study of Fabrazyme in Pediatric Patients With Fabry Disease

NCT00074958 ·Status: COMPLETED ·Phase: PHASE2

A Fabry Disease Gene Therapy Study

NCT04040049 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

NCT04804566 ·Status: COMPLETED

MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study

NCT03683966 ·Status: UNKNOWN

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

NCT07721025 ·Status: RECRUITING ·Phase: PHASE2

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

NCT00526071 ·Status: TERMINATED ·Phase: PHASE2

A Study of Replagal in Treatment-naïve Adults With Fabry Disease

NCT04840667 ·Status: TERMINATED ·Phase: PHASE3

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

NCT00864851 ·Status: COMPLETED ·Phase: PHASE3

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

NCT05698901 ·Status: RECRUITING

Diagnostic Role of Renal Biopsy in Patients With Fabry Disease

NCT06801288 ·Status: COMPLETED

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

NCT05689164 ·Status: TERMINATED ·Phase: PHASE3

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

NCT04143958 ·Status: WITHDRAWN ·Phase: PHASE4